Mechanisms of cancer-related fatigue.

Cancer-related fatigue (CRF) is one of the most prevalent symptoms patients with cancer experience, both during and after treatment. CRF is pervasive and affects patients' quality of life considerably. It is important, therefore, to understand the underlying pathophysiology of CRF in order to develop useful strategies for prevention and treatment. At present, the etiology of CRF is poorly understood and the relative contributions of the neoplastic disease, various forms of cancer therapy, and comorbid conditions (e.g., anemia, cachexia, sleep disorders, depression) remain unclear. In any individual, the etiology of CRF probably involves the dysregulation of several physiological and biochemical systems. Mechanisms proposed as underlying CRF include 5-HT neurotransmitter dysregulation, vagal afferent activation, alterations in muscle and ATP metabolism, hypothalamic-pituitary-adrenal axis dysfunction, circadian rhythm disruption, and cytokine dysregulation. Currently, these hypotheses are largely based on evidence from other conditions in which fatigue is a characteristic, in particular chronic fatigue syndrome and exercise-induced fatigue. The mechanisms that lead to fatigue in these conditions provide a theoretical basis for future research into the complex etiology of this distressing and debilitating symptom. An understanding of relevant mechanisms may offer potential routes for its prevention and treatment in patients with cancer.Disclosure of potential conflicts of interest is found at the end of this article.

[1]  R. Blakely,et al.  The Proinflammatory Cytokines Interleukin-1beta and Tumor Necrosis Factor-Alpha Activate Serotonin Transporters , 2006, Neuropsychopharmacology.

[2]  B. Schermer,et al.  Upregulation of RGS7 may contribute to tumor necrosis factor-induced changes in central nervous function , 1999, Nature Medicine.

[3]  M. Campbell,et al.  Red blood cell magnesium and chronic fatigue syndrome , 1991, The Lancet.

[4]  M. Fernstrom,et al.  Exercise, serum free tryptophan, and central fatigue. , 2006, The Journal of nutrition.

[5]  M. Tisdale Biology of cachexia. , 1997, Journal of the National Cancer Institute.

[6]  J. Davis,et al.  Effect of increased brain serotonergic activity on endurance performance in the rat. , 1992, Acta physiologica Scandinavica.

[7]  S. Lightman,et al.  Inflammatory Disease as Chronic Stress , 1998, Annals of the New York Academy of Sciences.

[8]  J. Holm,et al.  Obstructive Jaundice Results in Increased Liver Expression of Uncoupling Protein 2 and Intact Skeletal Muscle Glucose Metabolism in the Rat , 2002, Scandinavian journal of gastroenterology.

[9]  J. Nortier,et al.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Lévi,et al.  [Study of circadian rhythms of activity by actometry: preliminary results in 30 patients with metastatic colorectal cancer]. , 1996, Pathologie-biologie.

[11]  F. Lévi,et al.  Non‐invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer , 1998, International journal of cancer.

[12]  T. Dinan,et al.  Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. , 1992, BMJ.

[13]  D G Stuart,et al.  Neurobiology of muscle fatigue. , 1992, Journal of applied physiology.

[14]  S. Gandevia Spinal and supraspinal factors in human muscle fatigue. , 2001, Physiological reviews.

[15]  M. Tisdale Anorexia and Cachexia , 2005 .

[16]  K. Kawasaki,et al.  Caerulein, a cholecystokinin-related peptide, depresses somatic function via the vagal afferent system. , 1983, Life sciences.

[17]  K. Lesch,et al.  Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6 , 1998, Neurochemistry International.

[18]  M. Tisdale Wasting in cancer. , 1999, The Journal of nutrition.

[19]  S. Dickerson,et al.  Diurnal cortisol rhythm and fatigue in breast cancer survivors , 2005, Psychoneuroendocrinology.

[20]  David Spiegel,et al.  Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? , 2003, Brain, Behavior, and Immunity.

[21]  R J Maughan,et al.  Evidence for a possible role of 5‐hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5‐HT re‐uptake inhibitor, reduces the capacity to perform prolonged exercise , 1992, Experimental physiology.

[22]  P. Dagnelie,et al.  Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[23]  G. Priore,et al.  Adrenal function following high-dose steroids in ovarian cancer patients. , 1995, Gynecologic oncology.

[24]  F. Lévi,et al.  Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens. , 1996, British Journal of Cancer.

[25]  R. Dantzer,et al.  Cytokine-induced sickness behaviour: mechanisms and implications , 2002, Trends in Neurosciences.

[26]  J. Davis,et al.  Effects of Branched-Chain Amino Acids and Carbohydrate on Fatigue During Intermittent, High-Intensity Running , 1999, International journal of sports medicine.

[27]  P. Andrews,et al.  Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment , 2002, Supportive Care in Cancer.

[28]  P Hassmén,et al.  Effect of branched-chain amino acid supplementation on mental performance. , 1991, Acta physiologica Scandinavica.

[29]  P. Jacobsen,et al.  Distinguishing fatigue and depression in patients with cancer. , 2003, Seminars in clinical neuropsychiatry.

[30]  Z. Kronfol,et al.  Circadian Immune Measures in Healthy Volunteers: Relationship to Hypothalamic-Pituitary-Adrenal Axis Hormones and Sympathetic Neurotransmitters , 1997, Psychosomatic medicine.

[31]  L. Blackshaw,et al.  Effects of 5-hydroxytryptamine on discharge of vagal mucosal afferent fibres from the upper gastrointestinal tract of the ferret. , 1993, Journal of the autonomic nervous system.

[32]  D. McMillan,et al.  The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer , 2005, Cancer.

[33]  H. Withers,et al.  Induction of acute phase gene expression by brain irradiation. , 1995, International journal of radiation oncology, biology, physics.

[34]  M. Sahoo,et al.  Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: Dopaminergic, noradrenergic and thyroid correlates , 2007, Psychoneuroendocrinology.

[35]  E. Bosmans,et al.  Increased 24‐hour urinary cortisol excretion in patients with post‐traumatic stress disorder and patients with major depression, but not h patients with fibromyalgia , 1998, Acta psychiatrica Scandinavica.

[36]  M. Swain,et al.  Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis. , 1993, The Journal of clinical investigation.

[37]  J. Bellanti,et al.  Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[38]  C. Fürst,et al.  Symptoms in advanced cancer: relationship to endogenous cortisol levels , 2003, Palliative medicine.

[39]  J. Davis,et al.  Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. , 1993, Journal of applied physiology.

[40]  M. Kris,et al.  Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Nemeroff,et al.  Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.

[42]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[43]  G. Morrow,et al.  Management of Cancer-Related Fatigue , 2005, Cancer investigation.

[44]  R. Aquilani,et al.  Altered muscle energy metabolism in post-absorptive patients with chronic renal failure. , 1997, Scandinavian journal of urology and nephrology.

[45]  D. Cella,et al.  Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. , 1997, Journal of pain and symptom management.

[46]  R. Stern,et al.  Reduction in serum cortisol after platinum based chemotherapy for cancer: a role for the HPA axis in treatment-related nausea? , 2002, Psychophysiology.

[47]  Circadian function in patients with advanced non-small-cell lung cancer , 2005, British Journal of Cancer.

[48]  M. Antoni,et al.  Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  E. Bruera,et al.  Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. , 2004, Cytokine.

[50]  D. Hallahan,et al.  The role of cytokines in radiation oncology. , 1993, Important advances in oncology.

[51]  S. Ferketich,et al.  The Development of an Instrument to Measure the Subjective Dimension of Fatigue , 1989 .

[52]  J. Griggs,et al.  Effect of paroxetine hydrochloride (Paxil®) on fatigue and depression in breast cancer patients receiving chemotherapy , 2005, Breast Cancer Research and Treatment.

[53]  G. Demetri,et al.  Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. , 2002, The oncologist.

[54]  P. Platen,et al.  Influence of paroxetine, branched-chain amino acids and tyrosine on neuroendocrine system responses and fatigue in humans. , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[55]  H. Kraemer,et al.  Diurnal cortisol rhythm as a predictor of breast cancer survival. , 2000, Journal of the National Cancer Institute.

[56]  A. Chaudhuri,et al.  Fatigue in neurological disorders , 2004, The Lancet.

[57]  D. Laude,et al.  Effects of conditioned running on plasma, liver and brain tryptophan and on brain 5‐hydroxytryptamine metabolism of the rat , 1985, British journal of pharmacology.

[58]  M. Perlis,et al.  Cancer-related fatigue and sleep disorders. , 2007, The oncologist.

[59]  J. Krueger,et al.  Vagotomy Blocks the Induction of Interleukin-1β (IL-1β) mRNA in the Brain of Rats in Response to Systemic IL-1β , 1998, The Journal of Neuroscience.

[60]  Norihiro Sadato,et al.  Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome , 2004, BMC neurology.

[61]  S. Maier,et al.  Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. , 1998, Psychological review.

[62]  D. Perrett,et al.  Effect of sustained exercise on plasma amino acid concentrations and on 5-hydroxytryptamine metabolism in six different brain regions in the rat. , 1989, Acta physiologica Scandinavica.

[63]  G. Chrousos,et al.  Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. , 2002, Endocrinology and metabolism clinics of North America.

[64]  J. Hill,et al.  Stimulation of vagal afferents inhibits locomotion in mesencephalic cats. , 1993, Journal of applied physiology.

[65]  Patricia A. Ganz,et al.  Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors , 2002, Psychosomatic medicine.

[66]  P. Hinds,et al.  NCCN Practice Guidelines for Cancer-Related Fatigue. , 2000, Oncology.

[67]  K. Blesch,et al.  Correlates of fatigue in people with breast or lung cancer. , 1991, Oncology nursing forum.

[68]  James F. Jones,et al.  Chronic fatigue syndrome: identification of distinct subgroups on the basis of allergy and psychologic variables. , 1998, The Journal of allergy and clinical immunology.

[69]  D. Cella,et al.  The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. , 1997, Seminars in hematology.

[70]  M. Goldberg,et al.  EFFECT OF INFLAMMATORY CYTOKINES ON HYPOXIA-INDUCED ERYTHROPOIETIN PRODUCTION , 1992 .

[71]  C. Kilts,et al.  Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[72]  A. Berger,et al.  Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. , 1998, Oncology nursing forum.

[73]  J. Krueger,et al.  Subdiaphragmatic vagotomy blocks the sleepand fever-promoting effects of interleukin-1β. , 1997, American journal of physiology. Regulatory, integrative and comparative physiology.

[74]  F. Dhabhar,et al.  The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions , 1997, Brain Research Reviews.

[75]  James F. Jones,et al.  Chronic fatigue syndrome: a working case definition. , 1988, Annals of internal medicine.

[76]  A. Paintal Sensations From J Receptors , 1995 .

[77]  A. Cleare,et al.  Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. , 2001, The Journal of clinical endocrinology and metabolism.

[78]  P. Ganz,et al.  Altered Cortisol Response to Psychologic Stress in Breast Cancer Survivors With Persistent Fatigue , 2005, Psychosomatic medicine.

[79]  S. Shirreffs,et al.  The effect of acute branched-chain amino acid supplementation on prolonged exercise capacity in a warm environment , 2004, European Journal of Applied Physiology.

[80]  Q. Springer-Verlag Fatigue, depression and quality of life in cancer patients: how are they related? , 1998 .

[81]  S. Henriksen,et al.  Effects of corticotropin-releasing factor and growth hormone-releasing factor on sleep and activity in rats. , 1986, Neuroendocrinology.

[82]  R. Dantzer,et al.  Inhibition of vagally mediated immune-to-brain signaling by vanadyl sulfate speeds recovery from sickness. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[83]  S. Sisto,et al.  Reduced oxidative muscle metabolism in chronic fatigue syndrome , 1996, Muscle & nerve.

[84]  J. Groopman,et al.  Chemotherapy-induced anemia in adults: incidence and treatment. , 1999, Journal of the National Cancer Institute.

[85]  C. Iber,et al.  Extreme dyspnea from unilateral pulmonary venous obstruction. Demonstration of a vagal mechanism and relief by right vagotomy. , 1987, The American review of respiratory disease.

[86]  Stefano Iacobelli,et al.  Elevated Serum Cytokines Correlated with Altered Behavior, Serum Cortisol Rhythm, and Dampened 24-Hour Rest-Activity Patterns in Patients with Metastatic Colorectal Cancer , 2005, Clinical Cancer Research.

[87]  M. Sawka,et al.  Branched-chain amino acid supplementation and human performance when hypohydrated in the heat. , 2004, Journal of applied physiology.

[88]  M. Mormont,et al.  Contribution of the rest–activity circadian rhythm to quality of life in cancer patients , 2002, Chronobiology international.

[89]  A. Steiger,et al.  Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. , 1988, Neuroendocrinology.

[90]  T. Dinan,et al.  Blunted adrenocorticotropin and Cortisol responses to corticotropin‐releasing hormone stimulation in chronic fatigue syndrome , 1998, Acta psychiatrica Scandinavica.

[91]  P. Cowen,et al.  Increased brain serotonin function in men with chronic fatigue syndrome , 1997, BMJ.

[92]  P. Flynn,et al.  Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  G. Lyman,et al.  Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. , 1999, Journal of pain and symptom management.

[94]  J. Krueger,et al.  Vagotomy attenuates but does not prevent the somnogenic and febrile effects of lipopolysaccharide in rats. , 1998, The American journal of physiology.

[95]  F. Lévi,et al.  Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in humans. , 1986, Anticancer research.

[96]  F. Lévi,et al.  Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors , 2005, Journal of Cancer Research and Clinical Oncology.

[97]  Eva Blomstrand,et al.  Branched-chain amino acids and central fatigue. , 2006, The Journal of nutrition.

[98]  V. Mock,et al.  Assessment and management of cancer-related fatigue in adults , 2003, The Lancet.

[99]  T. Dinan,et al.  Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome , 1997, Psychoneuroendocrinology.

[100]  G. Kemp,et al.  Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle , 1998, Neuromuscular Disorders.

[101]  S. Jamar Fatigue in Women Receiving Chemotherapy for Ovarian Cancer , 1989 .

[102]  H. Poulsen,et al.  Assessment of the hypothalamo-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumor. , 2003, The Journal of clinical endocrinology and metabolism.

[103]  J. Singer,et al.  Phase I-II trial of pentoxifylline for the prevention of transplant- related toxicities following bone marrow transplantation [published erratum appears in Blood 1992 Jun 15;79(12):3397] [see comments] , 1991 .

[104]  W. Jelkmann,et al.  Modulation of the production of erythropoietin by cytokines: in vitro studies and their clinical implications. , 1990, Contributions to nephrology.

[105]  A. Cleare,et al.  The neuroendocrinology of chronic fatigue syndrome. , 2003, Endocrine reviews.

[106]  F. Chaouloff Physiopharmacological interactions between stress hormones and central serotonergic systems , 1993, Brain Research Reviews.

[107]  M. Kalia Effects of certain cerebral lesions on the J reflex , 1973, Pflügers Archiv.

[108]  R. Kurzrock,et al.  Cytokine deregulation in cancer. , 2001, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[109]  J. Pickar The thromboxane A2 mimetic U-46619 inhibits somatomotor activity via a vagal reflex from the lung. , 1998, The American journal of physiology.

[110]  G. Peluso,et al.  Skeletal muscle metabolism in physiology and in cancer disease , 2003, Journal of cellular biochemistry.

[111]  C. Begg,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[112]  E. Jones Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy , 1999, The Lancet.

[113]  H. Coleridge,et al.  Afferent vagal C fibre innervation of the lungs and airways and its functional significance. , 1984, Reviews of physiology, biochemistry and pharmacology.

[114]  F. Holsboer,et al.  Acute Cortisol Administration Promotes Sleep Intensity in Man , 2004, Neuropsychopharmacology.

[115]  G. Bleijenberg,et al.  The effect of granisetron, a 5-HT3 receptor antagonist, in the treatment of chronic fatigue syndrome patients--a pilot study. , 2003, Netherlands Journal of Medicine.

[116]  D. McCloskey Kinesthetic sensibility. , 1978, Physiological reviews.

[117]  Jacobsen,et al.  Is Fatigue a Long-term Side Effect of Breast Cancer Treatment? , 1999, Cancer control : journal of the Moffitt Cancer Center.

[118]  D. Greenberg,et al.  Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. , 1993, Journal of pain and symptom management.

[119]  P. Sawchenko,et al.  Differential regulation of corticotropin-releasing factor mRNA in rat brain regions by glucocorticoids and stress , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[120]  R. Crow,et al.  A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. , 1996, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[121]  P. Ganz,et al.  Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  W. Saris,et al.  Ingestion of branched‐chain amino acids and tryptophan during sustained exercise in man: failure to affect performance. , 1995, The Journal of physiology.

[123]  P. Blower,et al.  Effect of Granisetron on Performance Status during High-Dose Interferon Therapy , 1999, Oncology.

[124]  D. Gemsa,et al.  Effects of interferon-gamma, interleukin-1 beta, and tumor necrosis factor-alpha on the serotonin metabolism in the nucleus raphe dorsalis of the rat. , 1997, Journal of neural transmission.

[125]  M. R. Visser,et al.  Fatigue, depression and quality of life in cancer patients: how are they related? , 1998, Supportive Care in Cancer.

[126]  M. Simmonds,et al.  Differences in physical performance between men and women with and without lymphoma. , 2003, Archives of physical medicine and rehabilitation.

[127]  S. Bailey,et al.  Branched-chain amino acids prolong exercise during heat stress in men and women. , 1998, Medicine and science in sports and exercise.

[128]  L. Färber,et al.  Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results. , 2000, Scandinavian Journal of Rheumatology. Supplement.

[129]  P. Hassmén,et al.  Influence of ingesting a solution of branched-chain amino acids on perceived exertion during exercise. , 1997, Acta physiologica Scandinavica.

[130]  P. Grasby,et al.  Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635 , 2005, Biological Psychiatry.

[131]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[132]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[133]  G. Aguilera Regulation of Pituitary ACTH Secretion during Chronic Stress , 1994, Frontiers in Neuroendocrinology.

[134]  S. Wessely,et al.  Contrasting neuroendocrine responses in depression and chronic fatigue syndrome , 1995, Biological Psychiatry.

[135]  M. Hotopf,et al.  Chronic fatigue and its syndromes , 1998 .

[136]  E. Tornquist,et al.  Key Aspects of Comfort: Management of Pain, Fatigue, and Nausea , 1989 .

[137]  E. Newsholme,et al.  The role of tryptophan in fatigue in different conditions of stress. , 1999, Advances in experimental medicine and biology.

[138]  P. Andrews,et al.  Fatigue associated with cancer and its treatment , 2002, Supportive Care in Cancer.

[139]  M. Wichers,et al.  The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. , 2002, The international journal of neuropsychopharmacology.

[140]  M. Demitrack,et al.  Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. , 1991, The Journal of clinical endocrinology and metabolism.

[141]  S. Landau,et al.  An investigation of hypothalamic-pituitary-adrenal axis hyperactivity in anorexia nervosa: the role of CRH and AVP. , 2007, Journal of psychiatric research.

[142]  J Lellouch,et al.  Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[143]  A qualitative study to explore the concept of fatigue/ tiredness in cancer patients and in healthy individuals , 1998 .

[144]  M. Opp,et al.  Corticotropin-releasing hormone (CRH) as a regulator of waking , 2001, Neuroscience & Biobehavioral Reviews.

[145]  J. Payne The trajectory of fatigue in adult patients with breast and ovarian cancer receiving chemotherapy. , 2002, Oncology nursing forum.

[146]  A. Chaudhuri,et al.  Fatigue and basal ganglia , 2000, Journal of the Neurological Sciences.

[147]  A. Farmer,et al.  Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome , 2005, Journal of psychopharmacology.

[148]  M. Dicato Anemia in cancer: some pathophysiological aspects. , 2003, The oncologist.

[149]  E. Hansson,et al.  On the potential role of glutamate transport in mental fatigue , 2004, Journal of Neuroinflammation.

[150]  A. Niijima,et al.  The afferent discharges from sensors for interleukin 1 beta in the hepatoportal system in the anesthetized rat. , 1996, Journal of the autonomic nervous system.

[151]  C. Kirschbaum,et al.  The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. , 1993, Neuropsychobiology.

[152]  F. López‐Soriano,et al.  Cytokines as mediators and targets for cancer cachexia. , 2006, Cancer treatment and research.

[153]  L. Nail,et al.  Fatigue and the cancer experience: the state of the knowledge. , 1994, Oncology nursing forum.

[154]  R. Figlin,et al.  Tumor necrosis factor: current clinical status and implications for nursing management. , 1988, Seminars in oncology nursing.

[155]  J. Davis,et al.  Possible mechanisms of central nervous system fatigue during exercise. , 1997, Medicine and science in sports and exercise.

[156]  M. Opp,et al.  Somnogenic and pyrogenic effects of interleukin-1beta and lipopolysaccharide in intact and vagotomized rats. , 1998, Life sciences.

[157]  A. Paintal,et al.  Vagal sensory receptors and their reflex effects. , 1973, Physiological reviews.

[158]  J. Davis,et al.  438 EFFECTS OF A SEROTONIN (5-HT) AGONIST DURING PROLONGED EXERCISE TO FATIGUE IN HUMANS , 1993 .

[159]  V. Mock,et al.  Exercise as an intervention for cancer-related fatigue. , 2004, Physical therapy.

[160]  D. Eckland,et al.  Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF-41 peptide and adenohypophysial proopiomelanocortin mRNA during chronic inflammatory stress. , 1992, Endocrinology.

[161]  E. Newsholme,et al.  Tryptophan, 5-hydroxytryptamine and a possible explanation for central fatigue. , 1995, Advances in experimental medicine and biology.

[162]  Eva Blomstrand,et al.  A role for branched-chain amino acids in reducing central fatigue. , 2006, The Journal of nutrition.

[163]  R. Omdal,et al.  The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis—a pilot study , 2005, Rheumatology International.

[164]  J. Phair,et al.  Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. , 1990, The Journal of infectious diseases.

[165]  J. Leiper,et al.  Paroxetine administration to influence human exercise capacity, perceived effort or hormone responses during prolonged exercise in a warm environment , 2004, Experimental physiology.

[166]  L C Harrison,et al.  Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. , 1998, Cytokine.

[167]  T. Lundeberg,et al.  Activation of Vagal Afferents after Intravenous Injection of Interleukin-1β: Role of Endogenous Prostaglandins , 1998, The Journal of Neuroscience.

[168]  F. Lévi,et al.  Circadian‐system alterations during cancer processes: A review , 1997, International journal of cancer.

[169]  P. Hassmén,et al.  Administration of branched-chain amino acids during sustained exercise — effects on performance and on plasma concentration of some amino acids , 2004, European Journal of Applied Physiology and Occupational Physiology.

[170]  M. Swain,et al.  Defective corticotropin‐releasing hormone mediated neuroendocrine and behavioral responses in cholestatic rats: Implications for cholestatic liver disease–related sickness behaviors , 1995, Hepatology.

[171]  L. Blackshaw,et al.  Effects of 5-hydroxytryptamine (5-HT) on the discharge of vagal mechanoreceptors and motility in the upper gastrointestinal tract of the ferret. , 1993, Journal of the autonomic nervous system.

[172]  D. Cella,et al.  Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.